Subjective cognitive decline (SCD) or anxiety symptoms in older individuals are independently associated with an increased risk of mild cognitive impairment (MCI) or dementia, a recent study has shown.
Crushing prasugrel tablets and administering it as a powder to patients with ST-segment elevation myocardial infarction (STEMI) prior to percutaneous coronary intervention (PCI) enhances the potency of platelet inhibition but fails to improve early coronary reperfusion, as shown in the results of the COMPARE CRUSH trial.
A multinutrient intervention has successfully reduced decline in cognition, function, brain atrophy, and disease progression in patients with prodromal Alzheimer’s disease (AD) over 3 years, results of the LipiDiDiet clinical trial have shown. Such benefits tend to increase with early and long-term intervention.
Researchers from the Hong Kong Baptist University (HKBU) have developed a novel contrast agent for brain MRI that enables real-time visualization and assessment of the size and number of amyloid-beta (Aβ) oligomers, a peptide that putatively plays a seminal role in synaptic loss in Alzheimer's disease (AD).
A prospective, randomized, double-blind, placebo-controlled, parallel-group pilot study shows that use of cerebrolysin in addition to standard-of-care management of aneurysmal subarachnoid haemorrhage (SAH) is well tolerated and feasible, but does not improve the 6-month global functional performance of patients.
A noninvasive bimodal sensory device that delivers combined stimulation of sound and electrical stimulation of the tongue reduces symptoms associated with ringing in the ears, or tinnitus, a study shows.
Remote electrical neurostimulation delivered via a device worn around the upper arm provides consistent relief in acute migraine patients treated in a real-world clinical setting, reducing the use of medications while having a favourable safety profile, as shown in a study.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.